Cancer patients tracked for years after experimental drug trial
NCT ID NCT05061823
Summary
This study provided continued access to the cancer drug bintrafusp alfa for 22 patients who had previously benefited from it in earlier trials. Its main goal was to collect long-term safety information and track how long patients lived after treatment. Researchers followed patients for up to five years after their last dose to monitor for any late side effects and overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Adana City Hospital - Parent Account
Adana, Turkey (Türkiye)
-
Asan Medical Center
Seoul, South Korea
-
BHI of Omsk region "Clinical Oncology Dispensary" - PARENT
Omsk, Russia
-
Centre Hospitalier de l'Ardenne - PARENT
Libramont, Belgium
-
Chang Gung Memorial Hospital,Linkou
Taoyuan, Taiwan
-
Communal Enterprise Volyn Regional Medical Center of Oncology of Volyn Regional Council - Department of Oncochemotherapy
Lutsk, Ukraine
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Lazio, Italy
-
Gachon University Gil Medical Center
Incheon, South Korea
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica
Valencia, Spain
-
Hospital General Universitario Gregorio Marañón
Madrid, Spain
-
Hospital Universitario Ramon y Cajal - Servicio de Oncologia
Madrid, Spain
-
NIH National Institutes of Health/GMB LTIB
Bethesda, Maryland, 20892, United States
-
National Cancer Center Hospital
Chūōku, Japan
-
National Cancer Center Hospital East
Kashiwa-shi, Japan
-
Saitama Medical University International Medical Center
Hidaka-shi, Japan
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
The Center for Cancer and Blood Disorders a Division of American Oncology Partners of Maryland, P.A.
Bethesda, Maryland, 20817, United States
-
Universitaetsklinikum Carl Gustav Carus TU Dresden - Medizinische Klinik I
Dresden, Germany
Conditions
Explore the condition pages connected to this study.